Pipeline

  Discovery
Candidate
Preclinical
Phase I
Partner
GPCR target for metabolic diseases +
Discovery
A2aR/A2bR antagonist (M1069) +
Phase I
EP4 receptor antagonist (DT-9081) +
Phase I
Anti-CCR8 antibody (DT-7012) +
Preclinical
PAR2 antagonist (DT-9045) +
Preclinical
Undisclosed GPCR targets +
Discovery
mGluR4/7/8 PAM +
Candidate
NPFFR antagonist +
Discovery
Multi-target collaboration for rare diseases +
Discovery
CXCR4 biased agonist +
Discovery